Alpha-1-antitrypsin

Added to your cart

Alpha-1-antitrypsin

Cart subtotal: £0.00

View cart (0) Checkout

#SKU P165-5

£67.37

Price excludes shipping costs.
To view our shipping costs click here.

Need to order this product in bulk?

Contact our team of experts to discuss your bulk requirements

Contact our expert team

Product Details

Alpha-1-antitrypsin (A1AT) is a glycoprotein with a molecular weight of 54 kDa and pI of 4.8. It is a serpine protease inhibitor which acts to limit the amount of cell damage and death at the tissue site. Different isoenzymes exist which together form the protease inhibitor system. Phenotype M is the most common and certain variants (S and Z) are associated with alpha-1-antitrypsin deficiency which can lead to emphysema and liver disease.
1mg
P165-5

More information

Attributes

Description

  • Shipping Information
  • Cool Pack
  • Abbreviations
  • A1AT
  • Specification
  • ≥96%
  • Recommended Use
  • Research and further manufacturing
  • Shelf Life
  • 5 years from DOM
  • Buffer
  • lyophilised from 0.02M NH4HCO3 solution. May contain traces of buffer salts.
  • Presentation Matrix
  • lyophilised from 0.02M NH4HCO3. May contain traces of buffer salts.
  • Purity/grade
  • >96%
  • Source
  • plasma
  • Applications
  • Biosensors, Clinical Chemistry, Control Manufacture, ELISA, Lateral Flow, Life Science
  • Molecular weight
  • 54kDa

Technical Documents

Certificates Of Analysis (166.03KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox